SPHRF (Starpharma Holdings) Common Stock : $159.86 Mil (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Starpharma Holdings Common Stock?

Starpharma Holdings's quarterly common stock declined from Jun. 2023 ($161.55 Mil) to Dec. 2023 ($161.12 Mil) and declined from Dec. 2023 ($161.12 Mil) to Jun. 2024 ($159.86 Mil).

Starpharma Holdings's annual common stock declined from Jun. 2022 ($169.13 Mil) to Jun. 2023 ($161.55 Mil) and declined from Jun. 2023 ($161.55 Mil) to Jun. 2024 ($159.86 Mil).

Starpharma Holdings Common Stock Historical Data

The historical data trend for Starpharma Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Common Stock Chart

Starpharma Holdings Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Common Stock

Get a 7-Day Free Trial

133.65

183.97

169.13

161.55

159.86

Starpharma Holdings Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Common Stock	Get a 7-Day Free Trial															169.13	162.40	161.55	161.12	159.86

Starpharma Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Starpharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

SPHRY:USA PQ6:Germany SPL:Australia

Address

4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067

Website

https://www.starpharma.com

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.